Abstract
A SYSTEMATIC REVIEW OF TREATMENT OUTCOME OF ANTIMALARIAL DRUGS AGAINST SARS-COV-2

Ehtesham Zahoor*, Philip Oreoluwa, Usman Haider Bhatti, Sana Saleem Tariq, Feyiyemi Aina Afolabi, Syed Furqan Shah, Ranjeet Kumar, Tesfatsiyon Mammo Ergando, Anum Awais and Sarfaraz Ahmad

ABSTRACT

Objective: The pandemic of the coronavirus disease (COVID-19) has become a public health emergency of international concern. There is no effectual drug at this time, although there is a dire need for an effective treatment against severe COVID-19. The purpose of this systematic review was to summarize the evidence regarding chloroquine (CQ)/hydroxychloroquine (HCQ) for COVID-19 treatment. Methods: We searched EMBASE, PubMed and three trial Registries for studies on the use of CQ/HCQ against COVID-19. Results: We included 12 articles (two narrative letters, two in-vitro studies, three editorial, two expert consensus paper, two national guideline documents, one complete study) and 41 ongoing clinical trials worldwide. CQ/HCQ seems to be effective in limiting the replication of SARS-CoV-2 (the virus causing COVID-19) in vitro. Conclusions: Even though the safety of CQ/HCQ has been established in clinical practice and there is also sufficient pre-clinical rationale and evidence for its effective use in other conditions that validate clinical research on CQ/HCQ against COVID-19. Moreover, the recent results of the trials are also not in favor of HCQ use against covid-19. However, clinical use against COVID-19 should either adhere to the MEURI framework or only after ethical approval after clinical trials as specified by WHO. The current situation holds an urgently needed safety data from high-quality clinical trials.

Keywords: SARS-CoV-2, COVID-19, Chloroquine, Hydroxychloroquine, Pneumonia, Coronavirus.


[Full Text Article]

Login





Forgot Password  |  Register

Indexing

Best Paper Awards

European Journal of Biomedical and Pharmaceutical Sciences (EJBPS) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.

Best Article of current issue :

Tangudu Nagabhusana Rao

Download Article : Click here

News & Updation

  • NEW AUGUST ISSUE PUBLISHED

    AUGUST 2020 Issue has been successfully launched on 1 August 2020.

  • EJBPS New Impact Factor

    Its our Pleasure to Inform you that EJBPS Impact Factor has been increased from 5.467 to 6.044, due to high quality Publication at International Level.

  • Index Copernicus Value

    EJBPS Received Index Copernicus Value 77.3, due to High Quality Publication in EJBPS at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in EJBPS coming Issue.

     

UG/PG/Ph.D Research Publication

Research Scholar of UG/PG/Ph.D can Submit their Research Article/Review Article/Case Study/Short Communication for Publication in EJBPS

Downloads

Copyright From

Covering Letter

                        Author Instruction 
 

PLAGERLUM REPORT